HER2 missense mutations have distinct effects on oncogenic signaling and migration

Daniel J. Zabransky, Christopher L. Yankaskas, Rory L. Cochran, Hong Yuen Wong, Sarah Croessmann, David Chu, Shyam M. Kavuri, Monica Red Brewer, D. Marc Rosen, W. Brian Dalton, Ashley Cimino-Mathews, Karen Cravero, Berry Button, Kelly Kyker-Snowman, Justin Cidado, Bracha Erlanger, Heather A. Parsons, Kristen M. Manto, Ron Bose, Josh LauringCarlos L. Arteaga, Konstantinos Konstantopoulos, Ben Ho Park

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Recurrent human epidermal growth factor receptor 2 (HER2) missense mutations have been reported in human cancers. These mutations occur primarily in the absence of HER2 gene amplification such that most HER2-mutant tumors are classified as "negative" by FISH or immunohistochemistry assays. It remains unclear whether nonamplified HER2 missense mutations are oncogenic and whether they are targets for HER2-directed therapies that are currently approved for the treatment of HER2 gene-Amplified breast cancers. Here we functionally characterize HER2 kinase and extracellular domain mutations through gene editing of the endogenous loci in HER2 nonamplified human breast epithelial cells. In in vitro and in vivo assays, the majority of HER2 missense mutations do not impart detectable oncogenic changes. However, the HER2 V777L mutation increased biochemical pathway activation and, in the context of a PIK3CA mutation, enhanced migratory features in vitro. However, the V777L mutation did not alter in vivo tumorigenicity or sensitivity to HER2-directed therapies in proliferation assays. Our results suggest the oncogenicity and potential targeting of HER2 missense mutations should be considered in the context of cooperating genetic alterations and provide previously unidentified insights into functional analysis of HER2 mutations and strategies to target them.

Original languageEnglish (US)
Pages (from-to)E6205-E6214
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number45
DOIs
StatePublished - Nov 10 2015

Fingerprint

Missense Mutation
Mutation
erbB-1 Genes
human ERBB2 protein
Gene Amplification
Epidermal Growth Factor Receptor
Neoplasms
Breast
Therapeutics
Epithelial Cells
Immunohistochemistry
Breast Neoplasms

ASJC Scopus subject areas

  • General

Cite this

HER2 missense mutations have distinct effects on oncogenic signaling and migration. / Zabransky, Daniel J.; Yankaskas, Christopher L.; Cochran, Rory L.; Wong, Hong Yuen; Croessmann, Sarah; Chu, David; Kavuri, Shyam M.; Brewer, Monica Red; Marc Rosen, D.; Brian Dalton, W.; Cimino-Mathews, Ashley; Cravero, Karen; Button, Berry; Kyker-Snowman, Kelly; Cidado, Justin; Erlanger, Bracha; Parsons, Heather A.; Manto, Kristen M.; Bose, Ron; Lauring, Josh; Arteaga, Carlos L.; Konstantopoulos, Konstantinos; Park, Ben Ho.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 45, 10.11.2015, p. E6205-E6214.

Research output: Contribution to journalArticle

Zabransky, DJ, Yankaskas, CL, Cochran, RL, Wong, HY, Croessmann, S, Chu, D, Kavuri, SM, Brewer, MR, Marc Rosen, D, Brian Dalton, W, Cimino-Mathews, A, Cravero, K, Button, B, Kyker-Snowman, K, Cidado, J, Erlanger, B, Parsons, HA, Manto, KM, Bose, R, Lauring, J, Arteaga, CL, Konstantopoulos, K & Park, BH 2015, 'HER2 missense mutations have distinct effects on oncogenic signaling and migration', Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 45, pp. E6205-E6214. https://doi.org/10.1073/pnas.1516853112/-/DCSupplemental
Zabransky, Daniel J. ; Yankaskas, Christopher L. ; Cochran, Rory L. ; Wong, Hong Yuen ; Croessmann, Sarah ; Chu, David ; Kavuri, Shyam M. ; Brewer, Monica Red ; Marc Rosen, D. ; Brian Dalton, W. ; Cimino-Mathews, Ashley ; Cravero, Karen ; Button, Berry ; Kyker-Snowman, Kelly ; Cidado, Justin ; Erlanger, Bracha ; Parsons, Heather A. ; Manto, Kristen M. ; Bose, Ron ; Lauring, Josh ; Arteaga, Carlos L. ; Konstantopoulos, Konstantinos ; Park, Ben Ho. / HER2 missense mutations have distinct effects on oncogenic signaling and migration. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 45. pp. E6205-E6214.
@article{d8a19a434e8a42cf9bdc53ab98251dd9,
title = "HER2 missense mutations have distinct effects on oncogenic signaling and migration",
abstract = "Recurrent human epidermal growth factor receptor 2 (HER2) missense mutations have been reported in human cancers. These mutations occur primarily in the absence of HER2 gene amplification such that most HER2-mutant tumors are classified as {"}negative{"} by FISH or immunohistochemistry assays. It remains unclear whether nonamplified HER2 missense mutations are oncogenic and whether they are targets for HER2-directed therapies that are currently approved for the treatment of HER2 gene-Amplified breast cancers. Here we functionally characterize HER2 kinase and extracellular domain mutations through gene editing of the endogenous loci in HER2 nonamplified human breast epithelial cells. In in vitro and in vivo assays, the majority of HER2 missense mutations do not impart detectable oncogenic changes. However, the HER2 V777L mutation increased biochemical pathway activation and, in the context of a PIK3CA mutation, enhanced migratory features in vitro. However, the V777L mutation did not alter in vivo tumorigenicity or sensitivity to HER2-directed therapies in proliferation assays. Our results suggest the oncogenicity and potential targeting of HER2 missense mutations should be considered in the context of cooperating genetic alterations and provide previously unidentified insights into functional analysis of HER2 mutations and strategies to target them.",
author = "Zabransky, {Daniel J.} and Yankaskas, {Christopher L.} and Cochran, {Rory L.} and Wong, {Hong Yuen} and Sarah Croessmann and David Chu and Kavuri, {Shyam M.} and Brewer, {Monica Red} and {Marc Rosen}, D. and {Brian Dalton}, W. and Ashley Cimino-Mathews and Karen Cravero and Berry Button and Kelly Kyker-Snowman and Justin Cidado and Bracha Erlanger and Parsons, {Heather A.} and Manto, {Kristen M.} and Ron Bose and Josh Lauring and Arteaga, {Carlos L.} and Konstantinos Konstantopoulos and Park, {Ben Ho}",
year = "2015",
month = "11",
day = "10",
doi = "10.1073/pnas.1516853112/-/DCSupplemental",
language = "English (US)",
volume = "112",
pages = "E6205--E6214",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "45",

}

TY - JOUR

T1 - HER2 missense mutations have distinct effects on oncogenic signaling and migration

AU - Zabransky, Daniel J.

AU - Yankaskas, Christopher L.

AU - Cochran, Rory L.

AU - Wong, Hong Yuen

AU - Croessmann, Sarah

AU - Chu, David

AU - Kavuri, Shyam M.

AU - Brewer, Monica Red

AU - Marc Rosen, D.

AU - Brian Dalton, W.

AU - Cimino-Mathews, Ashley

AU - Cravero, Karen

AU - Button, Berry

AU - Kyker-Snowman, Kelly

AU - Cidado, Justin

AU - Erlanger, Bracha

AU - Parsons, Heather A.

AU - Manto, Kristen M.

AU - Bose, Ron

AU - Lauring, Josh

AU - Arteaga, Carlos L.

AU - Konstantopoulos, Konstantinos

AU - Park, Ben Ho

PY - 2015/11/10

Y1 - 2015/11/10

N2 - Recurrent human epidermal growth factor receptor 2 (HER2) missense mutations have been reported in human cancers. These mutations occur primarily in the absence of HER2 gene amplification such that most HER2-mutant tumors are classified as "negative" by FISH or immunohistochemistry assays. It remains unclear whether nonamplified HER2 missense mutations are oncogenic and whether they are targets for HER2-directed therapies that are currently approved for the treatment of HER2 gene-Amplified breast cancers. Here we functionally characterize HER2 kinase and extracellular domain mutations through gene editing of the endogenous loci in HER2 nonamplified human breast epithelial cells. In in vitro and in vivo assays, the majority of HER2 missense mutations do not impart detectable oncogenic changes. However, the HER2 V777L mutation increased biochemical pathway activation and, in the context of a PIK3CA mutation, enhanced migratory features in vitro. However, the V777L mutation did not alter in vivo tumorigenicity or sensitivity to HER2-directed therapies in proliferation assays. Our results suggest the oncogenicity and potential targeting of HER2 missense mutations should be considered in the context of cooperating genetic alterations and provide previously unidentified insights into functional analysis of HER2 mutations and strategies to target them.

AB - Recurrent human epidermal growth factor receptor 2 (HER2) missense mutations have been reported in human cancers. These mutations occur primarily in the absence of HER2 gene amplification such that most HER2-mutant tumors are classified as "negative" by FISH or immunohistochemistry assays. It remains unclear whether nonamplified HER2 missense mutations are oncogenic and whether they are targets for HER2-directed therapies that are currently approved for the treatment of HER2 gene-Amplified breast cancers. Here we functionally characterize HER2 kinase and extracellular domain mutations through gene editing of the endogenous loci in HER2 nonamplified human breast epithelial cells. In in vitro and in vivo assays, the majority of HER2 missense mutations do not impart detectable oncogenic changes. However, the HER2 V777L mutation increased biochemical pathway activation and, in the context of a PIK3CA mutation, enhanced migratory features in vitro. However, the V777L mutation did not alter in vivo tumorigenicity or sensitivity to HER2-directed therapies in proliferation assays. Our results suggest the oncogenicity and potential targeting of HER2 missense mutations should be considered in the context of cooperating genetic alterations and provide previously unidentified insights into functional analysis of HER2 mutations and strategies to target them.

UR - http://www.scopus.com/inward/record.url?scp=84946763302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946763302&partnerID=8YFLogxK

U2 - 10.1073/pnas.1516853112/-/DCSupplemental

DO - 10.1073/pnas.1516853112/-/DCSupplemental

M3 - Article

C2 - 26508629

AN - SCOPUS:84946763302

VL - 112

SP - E6205-E6214

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 45

ER -